Compare AstraZeneca plc (AZN) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Logitech International SA — how do they compare? AstraZeneca plc trades at $158.24 (market cap $248.14B), while Logitech International SA trades at $102.13 (market cap $14.96B). The key difference: AstraZeneca plc is far larger — about 16.6× Logitech International SA's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | LOGI | |
|---|---|---|
Market Cap | $248.14B | $14.96B |
Sector | Health | Technology |
52-Week High | $209.48 | $126.69 |
52-Week Low | $147.06 | $85.84 |
Enterprise Value | $275.41B | $13.30B |
Dividend Yield | 2.01% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Logitech (LOGI) trades at $101.92, down 2.81% amid technical bearish signals and supply chain concerns. The stock shows strong fundamentals with three consecutive quarterly earnings beats, robust 35.29% ROE, and 16.28% net margins. Recent Q1 2027 results exceeded expectations with $1.85 EPS versus $1.26 expected, though a semiconductor supplier shutdown creates near-term uncertainty.
Outlook remains mixed with 26% upside to consensus $109.75 target but tempered by supply risks. Investment case hinges on Logitech's premium product demand and margin expansion potential, balanced against Q3 2027 supply constraints and divided analyst sentiment (26% Buy, 47% Hold, 26% Sell).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
